Investigating the genetics of Hodgkin lymphoma that doesn't respond to treatment
Official title: Deep Sequencing of Relapse and Refractory Hodgkin Lymphoma Genomes: A Study of Tumor Biology and Evolution
Funded at Washington University · NIH-10908251 · Data updated 2026-11-12
This study is looking at the genetic changes in Hodgkin lymphoma to find out why some patients don’t respond to standard treatments or have relapses, with the hope of discovering better treatment options for those who need them.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $194,367 |
| NIH project number | 5K22CA266743-02 |
| Project ID | NIH-10908251 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with relapsed or refractory Hodgkin lymphoma who have not responded to standard treatment.
✕Less likely to help
Patients with newly diagnosed Hodgkin lymphoma who are responding well to standard treatments may not benefit from this research.
What this research studies
This research focuses on understanding the genetic changes in Hodgkin lymphoma, particularly in cases where the disease does not respond to standard treatments or relapses. By using advanced genome sequencing techniques, the study aims to identify specific genetic variants that contribute to treatment resistance. Patients with relapsed or refractory Hodgkin lymphoma will be analyzed to uncover the underlying tumor biology and evolution, which could lead to the development of more effective targeted therapies. The research seeks to improve risk assessment and treatment options for affected individuals.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies and improved survival rates for patients with relapsed or refractory Hodgkin lymphoma.
How similar studies have gone: Previous research has shown promise in using advanced sequencing technologies to understand cancer genetics, suggesting potential for success in this novel approach.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Gomez, Felicia — Washington University
- Study coordinator: Gomez, Felicia
Related research
Other NIH-funded projects on the same topics.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Trajectories of Neurotoxicity in young Hodgkin lymphoma patients
Aging Hodgkin lymphoma patients who are adolescents or young adults may face long-lasting brain and nerve-related side effects from their cancer treatment, and this study aims to map how those problems develop over time.
-
Combination therapy approach for non-Hodgkin lymphoma (NHL)
A Mayo Clinic team is testing a new combination treatment for non-Hodgkin lymphoma to improve responses in patients and in dogs with similar disease.
-
Multi-antigen T cell therapy for relapsed NHL
A patient-derived T cell therapy called MT-601 targets six tumor-associated antigens to help treat relapsed non-Hodgkin lymphoma after other therapies may have failed.
-
Personalized de‑intensification of therapy for NLP Hodgkin lymphoma
A clinician-scientist at Stanford is developing a patient-centered program to tailor and reduce therapy for nodular lymphocyte-predominant Hodgkin lymphoma using tumor and blood samples.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.